AstraZeneca/Daiichi's Enhertu shows survival benefit vs standard care in HER2+ gastric cancer patients, with 14.7 vs 11.4 ...

Arvinas' vepdegestrant shows 43% reduced risk of progression or death in ESR1-mutated breast cancer patients vs hormone ...

Appeals court denies HHS request to pause lower court order blocking federal agency restructuring plans that would cut 10,000 ...

Immatics has shared new survival data from a Phase 1b trial of its melanoma cell therapy candidate, bolstering expectations for a registrational study that it recently started.

Gilead and Merck made a strong case for combining Trodelvy and Keytruda in the first-line setting for an aggressive form of ...

Summit Therapeutics’ mixed results for its potential competitor to Merck’s Keytruda left an important question unanswered: ...

Summit Therapeutics' ivonescimab shows 48% PFS benefit but misses OS endpoint in Phase 3 lung cancer trial; drug's regulatory ...

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death for certain colorectal cancer ...

Youngblood has left Bristol Myers Squibb to join Acadia Pharmaceuticals as SVP of its rare disease franchise. She had a ...

Biopharma faces uncertainty in H2 2025 amid policy concerns and market challenges, with key healthcare conferences and ...

Since Bernard Ravina's medical training in neurology in the '90s, there have been few new therapies that treat a movement ...

After a slight delay, the FDA rejected Stealth BioTherapeutics' Barth syndrome drug application for elamipretide, but will ...